Fig. 3: Nobiletin functioned as a selective inducer for degradation of AR-V7.
From: Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
A Western blot of AR and AR-V7 in 22Rv1 cells exposed to nobiletin for 24 h.B Western blot analysis of AR and AR-V7 in 22Rv1 cells exposed to nobiletin (20 μM) for different lengths of time. C Immunofluorescence assay was performed using HA-tag antibody in 22Rv1 cells transfected with HA-AR-V7 plasmids for 48 h and exposed to nobiletin for 24 h. D Quantitative data of C are shown. Mean ± SD (n = 3). E Real-time quantitative PCR analysis of AR-V7 in 22Rv1 cells treated with nobiletin for 6 h. F Western blot of AR and AR-V7 protein level in 22Rv1 cells treated with nobiletin (10 μM) or DMSO for 12 h, and then exposed to cycloheximide (CHX). G Quantitative data of F are shown. Mean ± SD (n = 3). H Western blot analysis of AR and AR-V7 in 22Rv1 cells exposed to nobiletin with or without Bortezomib (BTZ) for 12 h. I Quantitative data of H are shown. Mean ± SD (n = 3). J Co-IP assay was performed using AR-V7 antibody and immunoblotted for K48-Ub and AR-V7 in 22Rv1 treated with nobiletin for 12 h, and exposed to MG132(10 μM) for 6 h before harvest. K Quantification of K48-ubiquitination levels of AR-V7 for J.
